Anti-Cancer MAbS Market: Opportunities, Strategies, Size, Share, and Analysis 2024-2033

Spread the love

Overview and Scope

Anticancer monoclonal antibodies (mAbs) are the antibodies used for monoclonal antibody therapy to target and destroy cancer cells. These mAbs are intended to bind to specific proteins or chemicals located on the surface of cancer cells, preventing cancer growth, and spread.

Sizing and Forecast

The anti-cancer mabs market size has grown rapidly in recent years. It will grow from $59.98 billion in 2023 to $66.1 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to increasing cancer incidence rates, growing understanding of cancer biology, rise in personalized medicine approaches, increased investment in research and development, growing patient awareness and demand..

The anti-cancer mabs market size is expected to see strong growth in the next few years. It will grow to $95.99 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in immunotherapy, increasing adoption of combination therapies, emergence of next-generation mabs, global efforts to address cancer burden, expansion of patient access programs.. Major trends in the forecast period include innovations in drug delivery technologies, integration of artificial intelligence in drug discovery, collaborations and partnerships in the pharma industry, advancements in biotechnology, car-t cell therapies..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

Segmentation & Regional Insights

The anti-cancer mabs market covered in this report is segmented –

1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types

2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications

3) By End User: Hospitals, Research Institutes, Other End Users

North America was the largest region in the anti-cancer MAbS market in 2023. Asia Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mabs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9041&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of cancer across the globe is expected to propel the growth of the anticancer MABs market going forward. Cancer refers to the disease that is a chronic disease that lasts for a longer time. Anticancer monoclonal antibodies (mAbs) are specifically designed to bind specific proteins found on cancerous cells as well as they use genetically engineered versions of the immune system’s own antibodies to target and destroy cancer cells, as a result, increasing the prevalence of cancer increases the demand for anticancer MABs market. For instance, in January 2022, according to PubMed, a US-based biomedical and life sciences journal, it is estimated that around 1.9 million new cancer cases are expected to be diagnosed globally, with 609,360 cancer deaths in the United States. Therefore, increasing the prevalence of cancer across the globe is propelling the growth of the anticancer mAbs market.

Key Industry Players

Major companies operating in the anti-cancer mAbs market are focused on developing innovative solutions, such as clinical trials, to gain a competitive edge in the market. Clinical trials are research studies that evaluate new treatments, medications, or devices in human participants, helping to determine whether new interventions are safe and effective. For instance, in April 2023, Y-mAbs Therapeutics Inc., a US-based clinical biopharmaceutical company, launched the Phase I Trial of GD2-Targeted Radioimmunotherapy. The Phase 1 trial evaluates the safety and efficacy of GD2-SADA, pre-targeted radioimmunotherapy (RIT) for treating certain GD2-positive solid tumors, including small cell lung cancer, sarcoma, and malignant melanoma. GD2-SADA is a novel RIT that uses a two-step approach to deliver radiation to tumor cells. First, the SADA protein is administered, which binds to GD2, a protein found on the surface of many solid tumors. Next, the radioactive ligand 177Lu-DOTA is administered, which binds to the SADA protein and delivers radiation to the tumor cells. This two-step approach is designed to minimize radiation exposure to healthy tissues.

The anti-cancer mabs market report table of contents includes: